Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-Cell Lymphomas Available In Europe On A Named-Patient Basis
Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID®, Biovest"s personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin"s lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Physicians in non-European countries may also contact idis to inquire about the potential availability of BiovaxID, as idis manages named-patient programs in more than 100 countries.
generic viagra online
Proposed Budget Cuts Worry Hospitals
The Wall Street Journal/Dow Jones Newswires reports on reaction to the Obama administration"s proposed cuts that may acutely affect hospitals. It notes: "President Obama last weekend called for $313 billion in savings over 10 years through adjustments in Medicare and Medicaid payments - a plan that a "deeply disappointed" American Hospital Association said would mean $220 billion in payment cuts to hospitals, on top of billions in other proposed Medicare cuts."
News of the day
Digital Mammography And Clinical Review Display Units Energising The European Markets For Medical Imaging Display Monitors, Finds Frost & Sullivan
Diagnostic display monitors have experienced slow growth in 2007 due to picture archiving and communication system (PACS) installations across radiology departments of European hospitals having reached saturation. However, favourable regulations mandating the sales of 5MP displays for digital mammography have ensured high-volume sales in several European countries. The increasing demand for clinical review display monitors from private practitioners has also ensured very high growth rates for medical imaging display monitors.
Diagnostics

First Minister Announces Funding For Second Phase Of Life Sciences Institute, Wales

First Minister Rhodri Morgan announced (date) that almost ÷£30 million of funding has been secured for phase two of the Institute of Life Science at Swansea University, with the promise of up to 650 jobs. The Welsh Assembly Government is providing ÷£8.5 million towards the cost of the project, which will also receive ÷£12.8 million from the European Regional Development Convergence Fund, ÷£6.4 million from Swansea University and ÷£1 million from Abertawe Bro Morgannwg University NHS Trust. Phase two of the Institute will include a clinical research centre and will also play a major role in developing new products and services for the healthcare industry. The first phase of the Institute, which opened in 2007, already boasts state-of-the-art laboratories researching areas such as cancer, obesity and diabetes. First Minister, Rhodri Morgan, said: "This massive announcement in the knowledge economy in Wales shows that we are not just seeking to survive this recession; we are also positioning Wales in the right place to be competitive in the upturn, when it comes." The Welsh Assembly Government is keen to facilitate and encourage collaboration between business and our world-class universities. With the second phase of the Institute of Life Science we can further develop and support the growing Life Science knowledge cluster in south west Wales, the UK and around the world." Deputy First Minister, Ieuan Wyn Jones, welcomed the announcement: "This is a major boost for the economy of south west Wales as well as a significant step forward for research and development. This new phase of the Institute will not only create new jobs in the region but it will also have the ability to support hundreds of businesses through technology and research." Health Minister, Edwina Hart, added: "This demonstrates the importance we place on medical research and the benefits it can deliver. The work at the Institute of Life Science complements the on-going studies and developments at the National Institute for Health and Social Care Research which was established earlier this year as part of the Welsh Assembly Government"s commitment to support and stimulate health and social care research to improve the health and well being of people in Wales." Vice-Chancellor for Swansea University, Professor Richard B. Davies, said: "This announcement is hugely significant for Swansea University. The recent UK Research Assessment Exercise showed the high quality of research in the vibrant Institute of Life Science. The new funding will allow the School of Medicine to build upon this success, increasing the scale of activity to create a globally competitive centre of excellence in life science research. The whole region and beyond will benefit from the resulting advances in medical practice and through the development of a cluster of high-technology life science companies." Acting Chief Executive of Abertawe Bro Morgannwg University NHS Trust, Calum Campbell, said: "The Trust is delighted with this announcement as it underlines the important role of research in pushing forward excellence in healthcare. The Trust and Swansea University have formed a close partnership which is built on this belief, and this second phase of the Institute of Life Science is very important." Welsh Assembly Government


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009